As of May 21, 2025, Somalogic Inc (SLGC) reports a Gross Margin of 55.60%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Somalogic Inc's Gross Margin
Over recent years, Somalogic Inc's Gross Margin has shown a moderate pattern. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2022-12-31 | 55.60% |
| 2021-12-31 | 59.01% |
| 2020-12-31 | 59.63% |
| 2019-12-31 | 44.02% |
This slight downward trend highlights how Somalogic Inc manages its operational efficiency and pricing power over time.
Comparing Somalogic Inc's Gross Margin to Peers
To better understand Somalogic Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Somalogic Inc (SLGC) | 55.60% |
| OmniAb Inc (OABI) | 7775.20% |
| Nautilus Biotechnology Inc (NAUT) | 7775.20% |
| MaxCyte Inc (MXCT) | 81.62% |
| BioLife Solutions Inc (BLFS) | 65.25% |
| Mesa Laboratories Inc (MLAB) | 61.64% |
Compared to its competitors, Somalogic Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.